Immix Biopharma Inc. (IMMX): Debt to Equity
The prospects for Immix Biopharma, Inc. (IMMX) depend on upcoming tests of new methods for combating autoimmune diseases, while the speculative nature of this micro-cap is already priced in. This chart on GURU.Markets shows that the total debt-to-equity ratio is 0.00, a critical factor given the risk of shareholder dilution due to R&D costs. Meanwhile, operational processes are protected by outsourcing vaccine production to third-party facilities.
%20Debt%20to%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_IMMX_-_Immix-Biopharma-Inc._-_Debt-to-Equity-Ratio "IMMX - Immix Total Debt to Capital over the range 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Immix Biopharma (IMMX)
Investors must balance growth potential against debt load to mitigate bankruptcy risks during periods of profit stagnation. By analyzing changes in the total debt-to-equity ratio, you assess the proportion of borrowed funds within the asset structure of Immix Biopharma, Inc. (IMMX), which is critical for maintaining the costly IMX-110 platform and expanding the network of specialized oncology centers within a closed medical circuit.